ArticleClinical immunology (Orlando, Fla.)
Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide.
Article in Clinical immunology (Orlando, Fla.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Emerging Technologies for the Treatment of COVID-19.Advances in experimental medicine and biology · 2021Article
- Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020.Emerging infectious diseases · 2020Article
- Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight.Acta pharmaceutica Sinica. B · 2020Review
- A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory ActivityFrontiers in pharmacology · 2020Article
- A specific oligodeoxynucleotide promotes the differentiation of osteoblasts via ERK and p38 MAPK pathways.International journal of molecular sciences · 2012Article
- An oligodeoxynucleotide that induces differentiation of bone marrow mesenchymal stem cells to osteoblasts in vitro and reduces alveolar bone loss in rats with periodontitis.International journal of molecular sciences · 2012Article
- An oligodeoxynucleotide with promising modulation activity for the proliferation and activation of osteoblast.International journal of molecular sciences · 2011Article
- Broad-spectrum drugs against viral agents.International journal of molecular sciences · 2008Article
- A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells.FEMS immunology and medical microbiology · 2007Article
- Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells.Acta pharmacologica Sinica · 2007Article
- Potential antivirals and antiviral strategies against SARS coronavirus infections.Expert review of anti-infective therapy · 2006Review
- Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).Perspectives in medical virology · 2006Review
- Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.Frontiers in immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supernatants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-alpha and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19+ B cells and CD56+ NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-gamma secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.